Menu di pagina
- IRE Research and Technology
- IRE Competitive Grants
- PerfeTTO
- INNOVA
- Immune Metabolism Dysregulation and Efficacy of Anti-PD-1/PD-L1 Agents in Non-Small Cell Lung Cancer (NSCLC)
- Artificial Intelligence and Machine Learning Based Risk Prediction Model for Improving Endometrial Cancer Clinical Management
- Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation after robot-assisted surgical treatment of genitourinary cancers
- Deciphering KEAPness for Improved Immunotherapy Prediction and Treatment
- MiRNA-based therapeutic approach to fight triple negative breast cancer
- Beyond the creation of a living biobank: dissecting the transcriptomic landscape of Gastro-entero-pancreatic neuroendocrine neoplasms
- Multidimensional assessment of virus-associated head and neck cancer patients for the discovery of predictive biomarkers to guide clinical intervention
- TArgeting drug resistant melanoma with miCroRNAs delivered by Lipid NanoparTICles (TACTIC)
- Addressing liver fibrosis prevention and treatment: an unbiased query on the hepatic microenvironment with a perspective targeting of the pro-fibrotic kinase HIPK2
- Analyses of HPV and host body fluid biomarkers as non-invasive strategy for detection of head and neck cancer relapse
- Deciphering Biology of R/R DLBCL Subtypes: miRNA Biomarkers for Optimizing Treatment and Survival
- Clinically approved drugs targeting pyruvate kinase M2: a drug repurposing pathway to move forward the treatment of glioblastoma
- Developing a Biobank Network Among Major Sarcoma Treatment Centers to Improve Biomedical Research
- Identification and Validation of Prognostic and Predictive Biomarkers, Including E3 Ubiquitin Ligases and MicroRNA Signature, for the Development of New Immunotherapeutic Approaches in Glioma
- Heal Italia
- D3 4 Health
- TRIglIFO2 project
- Poc MIMIT Project
- The PROMlSE project
- The 4Immunogenomics project
- Project ERBB2
- Project NANO-COVID-TEST
- Progetto DOMINO – Lazio Innova
- Project GEMMA – Lazio Innova
- Project COMETA
- Exploring the role of Bcl-2 family in the immune surveillance of melanoma: from mechanisms to therapeutic perspectives
- Exploring how endothelin-1/PIEZO axis intersects mechanical forces to fuel PARP inhibitor resistance in ovarian cancer
- The PROGRESS Project
- ULYSSES Project
- VerSiLiB Project
- PRODIGI Project
- LASERBLOOD Project
- BioCIPN Project
LASERBLOOD Project

Title: Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer
Acronym: LASERBLOOD
Start date: 1/01/2024
End date: 31/12/2027
Official website of the project: https://www.laserblood.eu/
Project description
The LASERBLOOD project is a pioneering initiative focused on developing an innovative in vitro diagnostic (IVD) test for the early detection of Pancreatic Ductal Adenocarcinoma (PDAC). This form of cancer remains one of the most lethal, with an alarming five-year survival rate below 10%. The urgency to improve early detection and diagnosis arises from the increasing incidence of PDAC due to aging populations, unhealthy lifestyles, and environmental factors. Currently, the lack of reliable biomarkers makes early screening nearly impossible, leading to late-stage diagnoses and poor survival outcomes.
To address this critical gap, LASERBLOOD leverages advances in fluorescence lifetime (FL) fingerprint analysis, applying it to personalized protein corona (PC) coatings on nanoparticles. This novel approach aims to develop a highly sensitive and specific diagnostic tool capable of detecting PDAC at its earliest stages, thereby significantly improving patient prognosis.
LASERBLOOD has structured its research into 5 distinct work packages (WPs), each contributing to the overarching objective of developing a reliable IVD test. Initial efforts are focused on defining the experimental setup for fluorescence lifetime (FL) analysis, selecting the optimal nanoparticle types, and determining the best conditions for PC formation. Key milestones include the successful engineering of an FL analysis prototype and the validation of FL fingerprints in preclinical mouse models.
Subsequent activities involve correlating FL signatures with various PDAC stages in mice, which has provided critical insights into disease progression. Subsequent research will test the LASERBLOOD approach in human plasma samples, paving the way for clinical validation. The project is also making significant strides in data analysis, utilizing bioinformatics tools to refine diagnostic accuracy and ensure reproducibility.
IFO-IRE is mainly involved in WP3 - Development of the IVD test for PDAC in mice.
List of Partecipants/Partner
- FLIM LABS SRL Coordinator
- UNIVERSITÀ SAPIENZA DI ROMA
- FONDAZIONE POLICLINICO UNIVERSITARIO CAMPUS BIO MEDICO
- ISTITUTI FIIOTERAPICI OSPITALIERI IFO-IRE
- UNIVERSITATSKLINIKUM ERLANGEN
- CROWDHELIX LIMITED
- COMPLEAR HEALTH
Purpose
The project aims to develop an in vitro diagnostic test for the early detection of PDAC using fluorescence-lifetime fingerprinting of the protein corona, whose optical signature acts as a disease-specific biomarker. The project first uses a genetically engineered mouse model to correlate bioluminescent imaging of PDAC progression with the fluorescence response measured in blood samples, thereby establishing a disease-progression fingerprint. In the second phase, this fingerprint will be validated in human samples to enable the development of a large-scale screening test for early PDAC detection.
Results
Guidelines for the experimental setup of FL analyses on PCs and on optimal experimental conditions for the FL analysis of PC with identification NP types and use of PDAC. orking experimental setup, including hardware and software for FL portotype. IVD procedure from correlation between FL and PDAC and Indicators.
Financial Support
This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No. 101130740, acronym LASEBLOOD, Call HORIZON-EIC-2023-PATHFINDEROPEN-01.
The total grant of the project is 3.386.586,25 euro
The GRANT assigned to IFO-IRE is 297.500,00 euro (codice CUP IFO-IRE: H83C23001770006)
Principal Investigator: Dr. Giulia Piaggio, Tumor Immunology and Immunotherapy Unit of IFO-IRE.




